{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:28:27Z","timestamp":1771637307507,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This report presented a case of 71-year-old man diagnosed with extensive-stage small cell lung cancer (ES-SCLC) who developed type 1 diabetic ketoacidosis (DKA) after 3 cycles of tislelizumab plus chemotherapy for the first time. The patient had no history of diabetes mellitus (DM). According to medical history and laboratory examination, the case was definitely diagnosed new-onset type 1 diabetic ketoacidosis induced by tislelizumab, a kind of immune checkpoint inhibitor. Despite the incidence of immune checkpoint inhibitor-induced type 1 diabetes mellitus (ICI-T1DM) is rare, the development of ICI-T1DM, especially type 1 diabetic ketoacidosis is life-threating without blood glucose monitoring and insulin therapy. Early identification of hyperglycemia and C-peptide depletion, as well as routine blood glucose monitoring during ICI treatment is essential to avoid lethal endocrine immune-related adverse event (irAE).<\/jats:p>","DOI":"10.3389\/fonc.2025.1498701","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:10:40Z","timestamp":1741237840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Jie","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/tca.2015.6.issue-3","article-title":"Current small cell lung cancer treatment in China","volume":"6","author":"Shi","year":"2015","journal-title":"Thorac Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.02.004","article-title":"Molecular profiles of small cell lung cancer subtypes: Therapeutic implications","volume":"20","author":"Schwendenwein","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.106","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): A multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus a case report and systematic review","volume":"181","author":"Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241241493","article-title":"Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option","volume":"2024","author":"Greene","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1248919","article-title":"Nivolumab-induced diabetes mellitus\u2014a case report with literature review of the treatment options","volume":"2023","author":"Daetwyler","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e255698","DOI":"10.1136\/bcr-2023-255698","article-title":"Immune checkpoint inhibitor-associated myocarditis and fulminant type I diabetes in a patient with metastatic non-small cell lung cancer","volume":"8","author":"Davis","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e25795","DOI":"10.1097\/MD.0000000000025795","article-title":"Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer","volume":"100","author":"Huang","year":"2021","journal-title":"Medicine(Baltimore)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e32076","DOI":"10.1097\/MD.0000000000032076","article-title":"Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report","volume":"101","author":"Wen","year":"2022","journal-title":"Medicine(Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e156330","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor-induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e57024","DOI":"10.7759\/cureus.57024","article-title":"Atezolizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer and pre-existing type 2 diabetes mellitus","volume":"16","author":"Narumoto","year":"2024","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the endocrine society, and the american diabetes association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden","year":"2018","journal-title":"Diabetol Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EDM-19-0152","article-title":"Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral","volume":"2020","author":"Kusuki","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2018:8981375","DOI":"10.1155\/2018\/8981375","article-title":"Fulminant diabetes in a patient with advanced melanoma on nivolumab","volume":"28","author":"Chokr","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"bcr2017220999","DOI":"10.1136\/bcr-2017-220999","article-title":"New onset diabetes after nivolumab treatment","author":"Capitao","year":"2018","journal-title":"BMJ Case Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1583280","article-title":"Thyroid hormone in the pediatric intensive care unit","volume":"5","author":"Radman","year":"2016","journal-title":"J Pediatr Intensive Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-023-02494-5","article-title":"Euthyroid sick syndrome and its association with complications of type 1 diabetes mellitus onset","volume":"94","author":"Marzuillo","year":"2023","journal-title":"Pediatr Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29670","article-title":"Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration","volume":"137","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/psp4.12880","article-title":"Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors","volume":"12","author":"Budha","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-2383","article-title":"Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab","author":"Feng","year":"2019"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e000453","DOI":"10.1136\/jitc-2019-000453","article-title":"Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors","volume":"81","author":"Desai","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2019","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1498701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:10:42Z","timestamp":1741237842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1498701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1498701"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1498701","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"article-number":"1498701"}}